Drug intelligence / Profile preview

Jango-Relieve

Development stage: Unknown
Lead developer: JangoPet
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

Jango-Relieve is a veterinary cell therapy product developed by JangoBio for the treatment of osteoarthritis, primarily in canine patients. The therapy consists of stromal vascular fraction (SVF), a multi-cellular component derived from adipose tissue that contains mesenchymal stem cells, endothelial cells, and various immune cells. Jango-Relieve is designed to provide regenerative and immunomodulatory effects within the joint, reducing inflammation and promoting tissue repair to alleviate the symptoms of osteoarthritis.

Brand names: Jango-Relieve
Other names: Jango-Relanve

Beyond the preview

Go deeper on Jango-Relieve.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jango-Relieve.

Explore the full profile